Y Intercept Hong Kong Ltd Invests $1.15 Million in Solventum Co. (NYSE:SOLV)

Y Intercept Hong Kong Ltd acquired a new stake in Solventum Co. (NYSE:SOLV) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 16,480 shares of the company’s stock, valued at approximately $1,149,000.

Other hedge funds have also added to or reduced their stakes in the company. MML Investors Services LLC lifted its holdings in shares of Solventum by 3.2% during the third quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after purchasing an additional 168 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its position in shares of Solventum by 4.2% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock valued at $346,000 after buying an additional 200 shares during the last quarter. National Bank of Canada FI boosted its holdings in Solventum by 4.0% in the second quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock valued at $314,000 after acquiring an additional 236 shares during the last quarter. IVC Wealth Advisors LLC increased its position in Solventum by 5.0% during the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock valued at $464,000 after purchasing an additional 318 shares during the period. Finally, KKM Financial LLC raised its holdings in Solventum by 7.9% during the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after purchasing an additional 319 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have recently weighed in on SOLV. Mizuho assumed coverage on shares of Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. BTIG Research initiated coverage on Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating for the company. Wolfe Research began coverage on Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. Morgan Stanley lifted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Stifel Nicolaus assumed coverage on shares of Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Solventum has an average rating of “Hold” and a consensus price target of $68.29.

Solventum Stock Up 1.1 %

Shares of SOLV opened at $70.46 on Thursday. The business’s fifty day moving average is $70.76 and its 200 day moving average is $63.03. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.